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Background/Aims:  Brain  natriuretic  peptide  (BNP)  levels  are  known  to  be  elevated  in  patients  with  chronic  kidney 
disease (CKD) and normal heart function. Therefore, the present study was performed to examine the effectiveness of 
BNP level in diagnosing heart failure in patients with CKD and  to determine its effects on survival rate and prognosis.
Method: A total of 182 patients with CKD who visited the hospital due to dyspnea of NYHA class II were included 
in the study. BNP levels were measured and echocardiography was performed to divide the subjects into groups with 
and  without  heart  failure.  Their  BNP  levels,  clinical  courses,  and  survival  rates  were  analyzed  retrospectively. 
Results: When BNP level was ≥858.5 pg/mL in CKD patients, heart failure could be diagnosed with sensitivity and 
specificity of 77% and 72%, respectively. Survival rate of the group with BNP levels of ≥858.8 pg/mL was significantly 
lower than that of the group with BNP level below this threshold (p=0.012) and multivariate analysis showed that BNP 
level,  age,  and  sex  affected  survival  rate  in  the  group  with  BNP  level  ≥858.8  pg/mL.
Conclusions: B N P  l e v e l s  o f  p a t i e n t s  w i t h  C K D  s h o w e d  a  p o s i t i v e  c o r r e l a t i o n  with  creatinine  levels,  and  the  critical 
point of BNP level for diagnosis of heart failure was 858.5 pg/mL. As the survival rate in patients with BNP level above 
the  critical  point  was  significantly  low,  this  level  was  a  useful  indicator  for  predicting  their  prognosis.  Care  should  be 
taken in interpreting BNP level because patients with stage 5 CKD may show a high concentration of BNP without heart 
failure.
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INTRODUCTION
Heart failure and coronary artery disease are major causes of 
death  in  patients  with  chronic  kidney  disease  (CKD)
1). 
Measurement of serum level of brain natriuretic peptide (BNP) is 
helpful  for  diagnosis  and  treatment  of  heart  failure  in  patients 
w i t h  n o r m a l  k i d n e y  f u n c t i o n
2) a n d  i s  k n o w n  t o  b e  a  u s e f u l  t e s t  
for the differential diagnosis of the concurrent presence of heart 
failure in patients visiting emergency care centers with the chief 
complaint  of  respiratory  distress
3).  However,  as  the  synthesis  of 
BNP  is  increased  within  myocardial  cells  and  BNP  clearance  in 
the  kidney  is  decreased  due  to  the  increased  water  content  in 
the body in patients with impaired renal function, the concentra-
t i o n  o f  s e r u m  B N P  i s  e l e v a t e d  i n  c o m p a r i s o n  t o  p a t i e n t s  w i t h  
normal  kidney  function.  Therefore,  different  criteria  must  be 
applied in subjects with impaired vs. normal renal function
4, 5). It 
is also necessary to examine whether the concentration of serum 
BNP  affects  the  survival  and  prognosis  in  patients  with  CKD  in The  Korean  Journal  of  Internal  Medicine:  Vol.  23,  No.  4,  December  2008 192
Figure  1.  The  classification  of  all  patients.
the  same  manner  as  in  normal  controls.
The present study was performed to examine the usefulness 
of serum BNP concentration in the diagnosis of heart failure and 
to determine its effects on the survival and prognosis in patients 
with  impaired  kidney  function.
MATERIALS AND METHODS
Patients 
Serum  BNP  concentration  was  measured  and  echocardio-
graphy was performed in 182 patients with a ≥6-month history 
of  impaired  renal  function  (glomerular  filtration  rate  [GFR]  <  60 
mL/min/1.73  m
2)  who  had  been  diagnosed  with  CKD.  The 
patients  were  recruited  when  they  visited  the  Department  of 
Internal  Medicine  (Division  of  Nephrology)  between  May  2001 
and  May  2006,  with  a  chief  complaint  of  respiratory  distress 
greater  than  New  York  Heart  Association  (NYHA)  class  II.  A 
retrospective  analysis  was  performed.  The  patient  diagnoses 
included 59 cases of CKD stage III, 52 cases of CKD stage IV, 
and  71  cases  of  CKD  stage,  of  whom  38  and  23  were 
undergoing  hemodialysis  and  peritoneal  dialysis,  respectively 
(Figure  1).
Methods 
The  following  laboratory  tests  were  performed:  body  index, 
E C G ,  c h e s t  r a d i o g r a p h y ,  a r t e r i a l  b l o o d  g a s  a n a l y s i s ,  s e r u m  
electrolyte,  complete  blood  cell  count,  and  serum  chemistry  for 
renal and hepatic function tests. Measurement of BNP level was 
performed  at  the  time  of  initial  outpatient  visit  for  patients  with 
CKD  who  were  not  undergoing  dialysis.  Measurements  were 
performed  prior  to  dialysis  because  the  serum  BNP  con-
centration was reported to be elevated prior to and to decrease 
following  dialysis  as  a  result  of  the  removal  of  fluids  in  dialysis 
patients
12, 13).  B l o o d  s a m p l e s  o f  3 - 5  m L  w e r e  c o l l e c t e d  i n  t e s t  
tubes containing a minimal amount of EDTA and centrifuged; the 
serum  was  isolated.  Quantitative  measurements  were  obtained 
by immunofluorescence labeling using a BNP kit (Triage
®; Biosite, 
San  Diego,  CA,  USA),  with  upper  and  lower  limits  of  detection 
o f  5 , 0 0 0  p g / mL  a n d  5  p g / mL ,  r e s p e c t i v e l y .
Echocardiography  was  performed  during  the  hospitalization 
period.  On  M-mode  test,  the  left  ventricular  diameter  and 
ejection  fraction  at  both  end-diastole  and  end-systole  were 
measured.  The  relaxation  function  was  evaluated  by  Doppler 
ultrasonography.  Renal  function  was  assessed  based  on 
creatinine  clearance  (Ccr)  in  24-h  urinalysis.  In  accordance  with 
the  Kidney  Disease  Outcomes  Quality  Initiative  (KDOQI) 
guidelines,  patients  were  classified  as  CKD  stage  III  (Ccr  30-59 
mL/min/1.73  m
2) ,  C K D  s t a g e  I V  ( C c r  1 5 - 2 9  m L / m i n / 1 . 7 3  m
2), 
and  CKD  stage  V  (Ccr  <  15  mL/min/1.73  m
2  or  patients 
undergoing  renal  replacement  therapy).  Diagnostic  criteria  for 
heart  failure  were  based  on  history,  radiological  findings,  and 
echocardiographic  findings,  which  included  clinical  symptoms 
fulfilling Framingham’s criteria, left ventricular ejection fraction of 
less than 50% on echocardiography, and left ventricular diameter 
at end-diastole greater than 5.5 cm. Patients with past histories 
o f  c h r o n i c  o b s t r u c t i v e  p u l m o n a r y  d i s e a s e ,  l i v e r  c i r r h o s i s ,  
m a l i g n a n t  t u m o r ,  o r  m u l t i p l e  t r a u m a  w e r e  e x c l u d e d  f r o m  t h e  
present  analysis.  A  follow-up  study  was  performed  based  on 
hospitalization records, medical records, and telephone interview 
to confirm whether any of the patients had died. For analysis of 
patient survival, considering death as the final event, all cases in 
which  transfer  or  loss  to  follow-up  occurred  were  treated  as 
having  dropped  out  of  the  study.  The  total  patient  population 
was divided into two groups: those with impaired and those with 
normal heart function. The serum BNP concentration, serological 
and  hematological  findings,  clinical  manifestations,  concurrent 
diseases,  and  echocardiographic  findings  were  compared 
b e t w e e n  t h e  t w o  g r o u p s ,  a n d  t h e  c o r r e l a t i o n s  b e t w e e n  s e r u m  
BNP  concentration  and  other  echocardiographic  findings  were 
also analyzed. Based on these findings, a retrospective analysis 
was  performed  for  the  factors  associated  with  clinical  course 
and  patient  survival.
Statistical  analysis 
Statistical  analyses  were  performed  using  SPSS  ver.  12.0 
(SPSS  Inc.,  Chicago,  IL,  USA).  All  data  are  expressed  as 
means±standard deviation (mean±SD). Student’ s t-test and the 
χ
2 t e s t  w e r e  u s e d  f o r  c o m p a r i s o n  o f  c o n t i n u o u s  a n d  d i s c o n -
tinuous variables, respectively, between the two groups. Multiple 
logistic  regression  analysis  was  performed  to  identify  the 
correlations  between  the  parameters  associated  with  heart 
failure.  Simple  linear  regression  analysis  was  performed  to 
i d e n t i f y  t h e  c o r r e l a t i o n  b e t w een  serum  BNP  concentration  and 
renal  function.  An  inter-group  comparison  of  the  correlation 
between  the  serum  BNP  concentration  and  echocardiographic 
findings  was  performed.  To  confirm  the  accuracy  of  measure-J a e  W o n  Y a n g ,  e t  a l .  B N P  a n d  h e a r t  f u n c t i o n  i n  c h r o n i c  k i d n e y  d isease 193
Variable
Total
(n=182)
CRF
* w i t h  C H F
†
(n=80)
CRF  without  CHF
(n=102)
p v a l u e
Age
BMI
‡
Systolic  BP
Diastolic  BP
LVH  in  EKG
Cardiomegaly  on  X-ray
Pulmonary  congestion  on  X-ray
Survival  duration  (month)
60.3±13.4
22.9±3.3
150.2±22.6
87.8±13.5
79  (43%)
84  (46%)
71  (39%)
50.3±35.6
60±15
22.3±3.1
146±20.9
87.2±13.5
29  (36%)
47  (59%)
42  (53%)
35.8±28.1
60±12
23.2±3.4
152.3±23.2
88.1±13.5
50  (49%)
37  (36%)
29  (28%)
51.6±32.1
NS
NS
NS
NS
NS
0.0001
0.001
0.026
CRF
*,  chronic  renal  failure;  CHF
†,  congestive  heart  failure;  BMI
‡,  body  mass  index
Table  1.  Basic  characteristics  and  clinical  findings  of  patients
ment  of  BNP  level  in  diagnosis  of  heart  failure  in  patients  with 
renal  failure,  receiver  operating  characteristic  (ROC)  curve 
analysis  was  performed.  The  cut-off  value  was  defined  as  the 
value  with  the  highest  sensitivity  and  specificity  on  the  ROC 
curve.  Patients  were  also  divided  into  two  groups  based  on 
whether  BNP  level  was  above  or  below  the  cut-off  value.  In 
these  two  groups,  analysis  of  patient  survival  was  performed 
using  the  Kaplan-Meier  method.  Statistical  significance  was  set 
at  p<0.05.
RESULTS
Patient  characteristics.
A total of 182 patients, including 99 men and 83 women with 
a  mean  age  of  60±13  years,  were  included  in  the  present 
study.  Patients  were  divided  into  two  groups  based  on  the 
presence  or  absence  of  heart  failure:  the  heart  failure  group 
(n=80) and the normal heart function group (n=102) . Mean age 
was 60±15 years in the heart failure group and 60±12 years in 
the  normal  heart  function  group;  this  age  difference  was  not 
statistically  significant.  Underlying  diseases  for  heart  failure 
included 41 cases of hypertension (51%), 27 cases of ischemic 
heart disease (33%), ten cases of dilated cardiomyopathy (12%), 
and two cases of valvular heart disease (4%). In the heart failure 
group,  underlying  diseases  for  ischemic  heart  disease  included 
19  cases  of  stable  angina  (70%),  four  cases  of  ischemic  heart 
failure  (15%),  three  cases  of  acute  myocardial  infarction  (11%), 
and  one  case  of  unstable  angina  (4%).  The  most  prevalent 
cause  of  kidney  disease  was  diabetic  nephropathy  (97  cases, 
54%),  followed  by  hypertensive  nephropathy  (64  cases,  35%), 
glomerulonephritis (15 cases, 8%), polycystic kidney disease (two 
cases, 1%), and idiopathic causes (four cases, 2%). In the heart 
failure group, the causes of renal disease included 41 cases of 
diabetic  nephropathy  (51%),  28  cases  of  hypertensive 
nephropathy (34%), and seven cases of glomerulonephritis (9%). 
In the normal heart function group, the causes of renal disease 
included  56  cases  of  diabetic  nephropathy  (55%),  36  cases  of 
hypertensive  nephropathy  (35%),  and  eight  cases  of  glo-
merulonephritis  (7%).  Thus,  diabetic  nephropathy  was  the  most 
prevalent  cause  of  renal  disease  in  both  groups.  Twenty-  eight 
(35%),  20  (25%),  and  32  (40%)  patients  in  the  heart  failure 
group,  and  31  (30%),  32  (31%),  and  39  (39%)  patients  in  the 
normal heart function group had stage 3, stage 4, and stage 5 
CKD,  respectively  (Figure  1).
Vital  signs  and  clinical  symptoms  (Table  1)
I n  t h e  t o t a l  p a t i e n t  p o p u l a t i o n ,  m e a n  s y s t o l i c  b l o o d  p r e s s u r e  
was 150.2±22.6 mmHg and mean diastolic blood pressure was 
87.8±13.5  mmHg.  There  were  no  significant  differences  in 
systolic  or  diastolic  pressure  between  the  heart  failure  and 
normal heart function groups (146±20.9 mmHg vs. 152.3±23.2 
mmHg, p=0.078, and 87.2±13.5 mmHg vs. 88.1±13.5 mmHg, 
p=0.684, respectively). The difference in number of patients with 
left ventricular hypertrophy on ECG between the heart failure and 
normal  heart  function  groups  was  not  significant  (29  vs.  50, 
respectively,  p=0.375).  Plain  chest  radiography  findings  sugge-
stive  of  pulmonary  edema  were  observed  in  42  patients  in  the 
heart  failure  group  and  in  29  patients  in  the  normal  heart 
function  group;  this  difference  was  significant  (p=0.001).  In 
addition,  findings  suggestive  of  cardiac  hypertrophy  were 
o b s e r v e d  i n  4 7  p a t i e n t s  i n  t h e  h e a r t  f a i l u r e  g r o u p  a n d  i n  3 7  
patients  in  the  normal  heart  function  group;  this  difference  was 
significant  (p=0.0001).
Laboratory  findings  (Table  2)
Mean  hemoglobin  level  in  the  total  patient  population  was 
10.2±5.5 g/dL.  It  was  9.9±1.9  g/dL  in  the heart failure group 
a n d  1 0 . 4 ± 6 . 7  g / d L  i n  t h e  n o r m a l  h e a r t  f u n c t i o n  g r o u p ;  t h i s  
difference  was  not  statistically  significant  (p=0.533).  On  liver 
function  test,  there  were  no  significant  differences  in  the  mean 
levels  of  the  following  parameters  between  the  heart  failure 
group  and  the  normal  heart  group,  respectively:  total  protein 
( 6 . 4 ± 0 . 9  g / d L ;  6 . 2 ± 1 . 0  vs.  6.5±0.9  g/dL,  p=0.257);  total The  Korean  Journal  of  Internal  Medicine:  Vol.  23,  No.  4,  December  2008 194
Variable
Total
(n=182)
CRF  with  CHF
(n=80)
CRF  without  CHF
(n=102)
p v a l u e
Hb
* ( g / d L )
Hct
† ( % )
Protein  (g/dL)
Albumin  (g/dL)
Cholesterol  (mg/dL)
AST  (U/L)
ALT  (U/L)
Calcium  (mg/dL)
Phosphate  (mg/dL)
Sodium  (mmol/L)
Potassium  (mmol/L)
BUN  (mg/dL)
Creatinine  (mg/dL)
R e s i d u a l  C c r  ( m l / m i n )
CK
‡ ( U / L )
LDH
§  (U/L)
CKMB  (ng/mL)
Troponin-I  (ng/mL)
CRP
∥ ( m g / d L )
BNP
¶ ( p g / m L )
10.2±5.5
29.2±5.3
6.4±0.9
3.3±0.6
166.1±50.1
33.2±97.9
26.8±68.6
9.3±2.3
5.6±6.8
135.2±12.2
4.5±0.9
54.5±28.7
6.2±3.8
33.0±12.6
133.7±172.6
284.1±114.5
7.1±19.4
1.2±2.1
2.7±4.8
1,667.5±1,914.2
9.9±1.9
29.1±5.2
6.2±1.0
3.2±0.7
167.2±52.3
38.6±12.8
31.1±24.3
8.85±1.1
5.2±3.5
133.7±15.1
4.6±0.9
57.1±31.6
5.9±4.0
33.7±12.8
174.4±259.3
291.0±105.7
7.9±15.1
2.1±7.2
2.9±5.6
3,003.6±1,967.1
10.4±6.7
29.4±5.5
6.5±0.9
3.4±0.6
165.5±49.1
23.1±12.9
18.9±16.2
10.1±9.4
6.4±10.5
136.0±3.9
4.5±0.9
53.0±26.9
6.3±3.75
32.6±12.5
111.4±91.6
280.3±119.3
6.0±28.8
0.4±1.7
2.3±3.2
942.9±1441.8
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
0.023
NS
NS
0.014
NS
0.0001
Hb
*,  hemoglobin;  Hct
†, h e m a t o c r i t ;  C K
‡, c r e a t i n e  k i n a s e ;  L D H
§,  lactate  dehydrogenase;  CRP
∥,  C-reactive  protein;  BNP
¶,  brain 
natriuretic  peptide
Table  2.  Laboratory  findings  of  patients
albumin  (3.3±0.6  g/dL;  3.2±0.7  vs.  3.4±0.6  g/dL,  p=0.082); 
total  cholesterol  (166.1±50.1  mg/dL;  167.2±52.3  vs.  165.5± 
49.1  mg/dL,  p=0.827);  and  triglyceride  (141.7±79.6  mg/dL; 
134.8±81.5  vs.  145.6±78.6  mg/dL,  p=0.395).  On  kidney 
function  test,  there  were  no  significant  differences  between  the 
heart  failure  group  and  the  normal  heart  group,  respectively,  in 
the  mean  levels  of  BUN  (54.5±28.7  mg/dL;  57.1±31.6  vs. 
53.1±26.9  mg/dL,  p=0.388)  or  creatinine  (6.2±3.8  mg/dL; 
5.9±4.0  vs.  6.3±3.7  mg/dL,  p=0.543).  Furthermore,  the  mean 
serum  electrolyte  concentrations  were  as  follows  for  the  heart 
failure  group  and  the  normal  heart  group,  respectively:  Na
+, 
135.2±12.2  mmol/L;  K
+,  4.5±0.9  mmol/L;  Cl
-,  104.3±6.4 
mmol/L;  Ca
2+,  9.3±2.3  mmol/L;  and  PO4
3-,  5.6±6.8  mmol/L. 
There were no significant differences in these values between the 
two  groups.  Mean  concentration  of  serum  BNP  was  1,667.4± 
1,914.1  pg/mL,  and  this  parameter  showed  a  significant 
difference between the heart failure group and the normal heart 
group, respectively (3,003.5±1,967.1 pg/mL vs. 942.8±1,441.8 
pg/mL,  p=0.0001).  The  overall  glomerular  filtration  rate  (GFR) 
was  33.1±12.6  mL/min  on  average,  and  was  not  significantly 
different  between  the  heart  failure  group  and  the  normal  heart 
group, respectively (33.7±12.8 mL/min  vs.  32.6±  12.5  ml/min, 
p=0.584).
Other  concurrent  diseases
Cerebral  infarction  and  stroke  were  concurrently  present  in 
eight patients in the heart failure group and in 18 patients in the 
normal  heart  function  group.  However,  this  difference  was  not 
significant  (p=0.612).  Cardiac  arrhythmia  was  more  prevalent  in 
the  heart  failure  group  (five  cases)  than  in  the  normal  heart 
function group (two cases) (p=0.032). Peripheral vascular occlu-
sive diseases were concurrently present in two patients in each 
groups,  but this  difference was  not  significant  (p=0.536). Thirty- 
seven  patients in the heart  failure group and 59 patients in  the 
n o r m a l  h e a r t  f u n c t i o n  g r o u p  h a d  a  h i s t o r y  o f  s m o k i n g ;  t h i s  
difference  was  not  significant  (p=0.341).  Thirty-five  and  55 
patients in the heart failure group and the normal heart function 
group,  respectively,  had  a  past  history  of  alcoholism;  this 
difference  was  not  significant  (p=0.298).
D r u g  u s e  h i s t o r y
Nitrate  drugs  were  administered  to  38  patients  in  the  heart 
failure group and 33 patients in the normal heart function group. 
The  difference  between  the  two  groups  was  not  significant 
(p=0.229).  Angiotensin  converting  enzyme  inhibitor  (ACE-I)  was 
administered  to  65  patients  in  the  heart  failure  group  and  78 
patients  of  the  normal  heart  function  group,  and  the  difference 
b e t w e e n  t h e  t w o  g r o u p s  w a s  n o t  s i g n i f i c a n t  ( p=0.344).  Angio-
tensin receptor blocker (ARB) was administered to 41 patients in 
the  heart  failure  group  and  45  patients  in  the  normal  heart 
function group, and the difference was not significant (p=0.873). 
Both  beta  blockers  and  diuretics  were  administered  at 
significantly higher frequencies in the heart failure group than  in 
the  normal  heart  function  group  (63  vs.  57  patients,  p=0.017, J a e  W o n  Y a n g ,  e t  a l .  B N P  a n d  h e a r t  f u n c t i o n  i n  c h r o n i c  k i d n e y  d isease 195
Variable
Total
(n=182)
CRF  with  CHF
(n=80)
CRF  without  CHF
(n=102)
p v a l u e
Ejection  fraction
LVMI
1
IVSd
2
LVDs
3
LVDd
4
PWDd
5
LA
6
DT
7
Pericardial  effusion
RWMA
8
56.0±15.6
166.7±48.9
1.15±0.26
3.89±0.97
5.58±0.74
1.14±0.26
4.88±0.63
198.2±60.6
63  (35%)
45  (25%)
39.5±10.4
186.5±46.2
1.04±0.2
4.7±0.8
5.9±0.7
1.04±0.3
4.9±0.6
159±49.9
31  (39%)
30  (38%)
59.3±8.8
166.1±50.7
1.2±0.2
3.4±0.6
5.3±0.6
1.2±0.1
4.8±0.5
220.9±54.8
32  (31%)
15  (15%)
0.001
0.04
0.001
0.002
0.001
0.002
NS
0.002
NS
0.001
LVMI
1,  l e f t  v e n t r i c u l a r  m a s s  i n d e x ;  I V S d
2,  end  diastolic  interventricular  septum  thickness;  LVDs
3,  end-systolic  left  ventricular  diameter; 
LVDd
4,  end-diastolic  left  ventricular  diameter;  PWDd
5,  end-diastolic  posterior  wall  thickness;  LA
6,  left  atrium;  DT
7,  deceleration  time; 
RWMA
8,  regional  wall  motion  abnormality
Table  3.  Echocardiographic  findings  of  patients.
and  67  vs.  48,  p=0.003,  respectively).
Echocardiography  (Table  3) 
On  echocardiography,  mean  overall  ejection  fraction  (EF)  in 
the  total  study  population  was  56.0±15.6%;  the  value  was 
s i g n i f i c a n t l y  l o w e r  i n  t h e  h e a r t  f a i l u r e  g r o u p  t h a n  i n  t h e  n o r m al 
heart function group (39.5±10.4% vs. 59.3±8.8%, respectively, 
p=0.00).  Mean  overall  left  ventricular  mass  index  (LVMI)  in  the 
total study population was 176.6±48.9 g/m
2, and the value was 
significantly  higher  in  the  heart  failure  group  than  in  the  normal 
heart function group (186.5±46.2 vs. 166.1±50.7 g/m
2, respec-
tively, p=0.04). Mean overall left ventricular end-systolic diameter 
( L V E S D )  w a s  3 . 8 ± 0 . 9  m m  ( 4 . 7 ± 0 . 8  vs.  3.4±0.6  mm);  mean 
overall  left  ventricular  end-diastolic  diameter  (LVEDD)  mm  was 
5.5±0.7  mm  (5.9±0.7  vs.  5.3±0.6  mm);  mean  overall  left 
ventricular interseptal thickness at end-systole was 1.1±0.2 mm 
(1.0±0.2  vs.  1.2±0.2  mm);  and  mean  overall  left  ventricular 
posterior  wall  thickness  at  end-diastole  was  1.1±0.2  mm 
(1.0±0.2 vs. 1.2±0.2 mm). The differences in these parameters 
between the two groups were all statistically significant (p=0.00). 
Mean  overall  fractional  shortening  (FS)  was  31.8±10.3%,  and 
was  significantly  lower  in  the  heart  failure  group  than  in  the 
normal heart function group (20.9±6.6 vs. 37.5±6.7%, p=0.00). 
Local  motor  disturbances  were  more  prevalent  in  the  heart 
failure group than in the normal heart function group (30 vs. 15 
cases,  respectively,  p=0.00).  The  numbers  of  cases  in  which 
pericardial effusion was classified as “mild” or “severe” were 
28 and 3 in the heart failure group and 28 and 4 in the normal 
heart  function  group,  respectively;  these  differences  were  not 
statistically  significant  (p=0.542)
Causes  of  death
Of the total of 80 patients in the heart failure group, 38 had 
died,  six  were  lost  to  follow-up,  and  36  were  currently  being 
followed-up  at  the  Outpatient  Clinic  of  the  Department  of 
Nephrology.  Of  the  total  of  102  patients  in  the  normal  heart 
function  group,  31  had  died,  eight  were  lost  to  follow-up,  and 
63  were  currently  being  followed-up  at  the  Outpatient  Clinic  of 
the  Department  of  Nephrology.  The  most  prevalent  cause  of 
death  was  cardiovascular  disease,  accounting  for  30  deaths  in 
the total study population (26 vs. 4 cases in the heart failure and 
normal heart function groups, respectively). This was followed by 
14 cases of sepsis (3 vs. 11 cases), 11 of idiopathic causes (3 
vs.  8  cases),  six  cases  of  cachexia  (all  in  the  normal  cardiac 
function  group),  five  cases  of  stroke  or  cerebrovascular 
hemorrhage (4 vs. 1 case), one case of gastrointestinal bleeding 
(in the normal heart function group), and one case of malignant 
tumor  (in  the  heart  failure  group). 
C o r r e l a t i o n  b e t w e e n  r e n a l  f u n c t i o n  a n d  s e r u m  B N P  c o n c e n -
tration  (Figure  2)
(1)  Difference  in  serum  BNP  concentration  between  the  two 
groups  in  patients  with  CKD  stage  3
The  serum  BNP  concentration  was  205.7±273.4  pg/mL  in 
the normal heart function group and 1,618.4±1,237.7 pg/mL in 
the heart failure group. Thus, it was significantly elevated in the 
heart  failure  group  (p=0.004).
(2)  Difference  in  serum  BNP  concentration  between  the  two 
groups  in  patients  with  CKD  stage  4
The  serum  BNP  concentration  was  284.0±435.6  pg/mL  in 
the normal heart function group and 2,713.0±2,023.3 pg/mL in 
the heart failure group. Thus, it was significantly elevated in the 
heart  failure  group  (p=0.000).
(3)  Difference  in  serum  BNP  concentration  between  the  two 
groups  in  patients  with  CKD  stage  5
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C K D  s t a g e  3      C K D  s t a g e  4      C K D  s t a g e  5  
p=0.004 p=0.000 p=0.009
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With  CHF
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Figure 2. Box plot of serum BNP levels in CKD stage 3 (A), CKD stage 
4  ( B ) ,  a n d  s t a g e  5  ( C )  a c c o r d i n g  t o  h e a r t  f u n c t i o n .
p=0.001
R  square=0.172
p=0.012
R  square=0.099
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Figure  3.  S c a t t e r  p l o t s  o f  l o g  B N P  w i t h  e j e c t i o n  f r a c t i o n  ( A )  a n d  d u r a t i o n  of  survival  (B).
in the normal heart function group and 3,519.1±1,935.8 pg/mL 
in  the  heart  failure  group.  Thus,  it  was  significantly  elevated i n  
the  heart  failure  group  (p=0.009).
(4)  Serum  BNP  concentration  depending  on  hemodialysis
A  comparison  of  BNP  level  depending  on  hemodialysis  was 
performed  in  all  patients  with  renal  failure,  without  considering 
heart  function.  The  results  indicated  BNP  levels  of  2,008.4± 
2,036.1  pg/mL  and  1,319.0±1,723.3  pg/mL  in  patients  who 
were  and  who  were  not  receiving  hemodialysis,  respectively 
(p=0.015).
(5) Difference in serum BNP concentration depending on CKD 
stage  in  the  normal  heart  function  group
I n  p a t i e n t s  i n  t h e  n o r m a l  h e a r t  f u n c t i o n  g r o u p  w i t h  c h r o n i c  
renal failure, the concentrations of serum BNP at CKD stages 3, 
4,  and  5  were  205±273.4,  284±435.6,  and  1,275±1,634.5 
pg/mL, respectively. There was no significant difference between 
CKD  stage  3  and  stage  4.  However  the  differences  between 
CKD stage 4 and stage 5 and between CKD stage 3 and stage 
5  were  significant  (p=0.018  and  p=0.006,  respectively).
(6) Difference in serum BNP concentration depending on CKD 
stage  in  the  heart  failure  group
In patients in the heart failure group with chronic renal failure, 
the  concentrations  of  serum  BNP  at  CKD  stages  3,  4,  and  5 
were  1,618±1,237.7,  2,713±2,023.3,  and  3,519±1,935.8 
pg/mL,  respectively.  There  were  no  significant  differences 
b e t w e e n  C K D  s t a g e  3  a n d  s t a g e  4  o r  b e t w e e n  C K D  s t a g e  4  
and 5. However, the difference between CKD stage 3 and stage 
5  was  significant  (p=0.011).
Correlations  between  serum  BNP  concentration  and  other 
parameters  (Figure  3)
(1)  Correlation  between  serum  BNP  concentration  and  left 
ventricular  ejection  fraction  on  echocardiography
There  was  a  significant  inverse  correlation  between  serum 
BNP concentration and left ventricular ejection fraction in patients 
with  CKD  (R
2=0.172,  p=0.001).
(2) Correlation between serum BNP concentration and patient 
survival
There  was  a  significant  inverse  correlation  between  serum 
BNP concentration and survival in patients with CKD (R
2=0.099, 
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(3)  Correlation  between  serum  BNP  concentration  and  LVMI 
on  echocardiography
There  was  a  significant  positive  correlation  between  serum 
BNP  concentration  and  LVMI  in  patients  with  CKD  (R
2=0.205, 
p=0.002).
Diagnostic  value  of  BNP  level  in  detecting  heart  failure  in 
patients  with  renal  failure  (Figure  4)
(1)  ROC  curve  of  total  patient  population
I n  t h e  t o t a l  p a t i e n t  p o p u l a t i o n ,  w h e n  B N P  l e v e l  w a s  8 5 8 . 5  
pg/mL  and  the  area  under  the  curve  (AUC)  was  0.823,  a 
diagnosis of heart failure was made with sensitivity of 77% and 
specificity  of  72%.
(2)  ROC  curve  of  patients  with  CKD  stages  3  or  4
In patients with CKD stages 3 or 4, when BNP level was 410 
pg/mL and the AUC was 0.94, a diagnosis of heart failure was 
ma d e  w i t h  s e n s i t i v i t y  o f  8 2 %  a n d  s p e c i f i c i t y  o f  9 0 % .
(3)  ROC  curve  of  patients  with  CKD  stage  5
I n  p a t i e n t s  w i t h  C K D  s t a g e  5 ,  w h e n  B N P  l e v e l  w a s  1 , 6 5 0  
pg/mL and the AUC was 0.806, a diagnosis of heart failure was 
ma d e  w i t h  s e n s i t i v i t y  o f  7 4 %  a n d  s p e c i f i c i t y  o f  7 6 % .
Analysis  of  patient  survival  (Figure  5)
( 1 )  I n  a l l  p a t i e n t s  ( C K D  s t a g e  3 - 5 ) ,  p a t i e n t  s u r v i v a l  w a s  
significantly lower in the group with BNP level higher than 858.8 
pg/mL  (p=0.012).
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Figure 4. The accuracy and reference value of serum BNP for diagnosing CH F in a ll patients (A ), in C KD  stage 3-4 (B ), a nd C KD  stage 5 (C)  by
ROC  curve.
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Figure 5. The cumulative survival rate using Kaplan-Meier method in patients with CKD stage 3-5 (A) and with renal replacement
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Variable
BNP  >  858.5  pg/mL BNP  <  858.5  pg/mL
H.R.  (Exp  B) p v a l u e
CI
†  (95%)
H.R.  (Exp  B) p v a l u e
CI  (95%)
lower upper lower upper
BNP
Age
Sex
DM
‡
Albumin  (g/dL)
LVMI
§ ( g / m
2)
Residual  CCr
∥ ( m L / m i n )
EF
¶ ( % )
1.001
1.025
1.198
1.225
0.581
0.996
1.004
0.978
0.017
0.022
0.630
0.623
0.051
0.259
0.758
0.263
0.999
1.001
0.579
0.545
0.337
0.989
0.979
0.942
1.004
1.051
2.463
2.750
1.003
1.003
1.030
1.017
1.000
1.032
1.334
0.781
0.489
0.988
0.986
0.886
0.334
0.035
0.478
0.425
0.035
0.107
0.388
0.631
1.000
1.001
0.601
0.427
0.251
0.974
0.954
0.841
1.000
1.065
2.961
1.434
0.950
1.002
1.019
1.262
DM
‡,  diabetes  mellitus;  LVMI
§,  left  ventricular  mass  index;  CCr
∥,  creatinine  clearance;  EF
¶,  ejection  fraction
Table  4.  Multivariable  analysis  of  risk  factors  for  CHF
(2)  In  patients  who  underwent  renal  replacement  therapy, 
survival  analysis  showed  that  patient  survival  was  significantly 
lower  in  the  group  with  BNP  level  higher  than  1,650  pg/mL 
(p=0.004).
Multivariate  analysis  (Table  4)
In  all  patients,  group  assignment  was  made  based  on  the 
c u t - o f f  v a l u e  o f  B N P  l e v e l  o f  8 5 8 . 5  p g / m L  o b t a i n e d  f r o m  t h e  
ROC  curve.  Multivariate  analysis  was  performed  to  identify  the 
independent  factors  affecting  patient  survival  in  each  group.  In 
the  group  with  BNP  level  exceeding  858.5  pg/mL,  the  factors 
associated  with  patient  survival  included  BNP  level  and  age.  In 
this group, however, sex, diabetes mellitus, left ventricular mass 
index, left ventricular ejection fraction, and residual renal function 
were  not  independent  factors  affecting  patient  survival.  In  the 
g r o u p  w i t h  B N P  l e v e l  l e s s  t h a n  8 5 8 . 5  p g / m L ,  t h e  f a c t o r s  
associated  with  patient  survival  were  age  and  albumin  level.  In 
this  group,  however,  other  parameters  were  not  independent 
factors  affecting  patient  survival.
DISCUSSION
In patients visiting the outpatient clinic with a chief complaint 
of  respiratory  distress,  it  is  critical  to  determine  whether  the 
etiology is of cardiogenic or non-cardiogenic origin to decide on 
an  appropriate  treatment  plan  and  to  estimate  prognosis. 
Respiratory  distress  symptoms  are  of  nonspecific  origin,  which 
cannot  be  differentially  diagnosed  based  on  an  interview  or 
routine laboratory tests. Echocardiography is costly and requires 
highly  trained  personnel.  Accordingly,  simplified  methods  have 
been  developed  for  measurement  of  serum  BNP  concentration 
and  their  use  has  become  widespread  in  the  assessment  of 
cardiac function
6, 7). BNP is a peptide hormone that is secreted 
in  response  to  muscular  relaxation  in  the  left  ventricle  and  is 
converted  to  two  biologically  active  forms:  c-BNP  and  N- 
terminal pro-BNP. N-terminal pro-BNP has a longer half-life and 
is more biologically stable than c-BNP, and it has greater clinical 
significance
8).  Recent  studies  have  shown  that  these  natriuretic 
peptides  accurately  indicate  the  treatment  response  and 
prognosis  as  well  as  fulfill  the  requirements  for  a  diagnosis  of 
heart  failure
9).
Left ventricular hypertrophy and left ventricular dysfunction are 
present  concurrently  in  60-80%  and  approximately  15%  of 
patients with CKD, respectively. A number of studies have been 
p e r f o r m e d  t o  e x a m i n e  t h e  d i a g n o s t i c  v a l u e  o f  B N P  l e v e l  i n  
detecting cardiogenic respiratory distress
10). In some studies, the 
serum  BNP  concentration  was  not  increased  in  comparison  to 
the normal value in patients with chronic renal diseases who had 
normal  kidney  function  and  showed  no  left  ventricular 
hypertrophy on echocardiography
5).  According  to  most  of  these 
studies, however, the volume of water content was elevated and 
renal  clearance  of  BNP  was  decreased  in  patients  with  CKD 
compared  to  patients  with  normal  kidney  function.  It  has  also 
been  reported  that  serum  BNP  concentration  is  elevated  in 
patients with chronic renal failure compared to those with normal 
kidney function
11, 12). However, the serum BNP concentration has 
a l s o  b e e n  s h o w n  t o  b e  a s s o c i a t e d  w i t h  l e f t  v e n t r i c u l a r  
dysfunction and left ventricular hypertrophy in patients with CKD 
or  end-stage  renal  disease.  Similar  to  observations  in  patients 
with  normal  kidney  function,  the  serum  BNP  concentration  has 
been reported to be a prognostic indicator of the occurrence of 
cardiovascular  disease  and  death  in  patients  with  CKD  or 
end-stage  renal  disease
13-15).
There is still a great deal of controversy regarding the cut-off 
value  of  BNP  level  in  the  diagnosis  of  heart  failure  in  patients 
with  CKD.  Only  a  small  number  of  studies  have  examined  the 
effects of BNP level on survival rate in these patients. Kim et al.
7) 
maintained  that  a  diagnosis  of  cardiac  failure  could  be  made 
with  sensitivity  and  specificity  of  77%  and  71%,  respectively, 
using  a  BNP  cut-off  value  of  higher  than  600  pg/L  in  patients 
with  chronically  impaired  kidney  function.  McCullough  et  al.
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reported that it would be appropriate to apply a diagnostic value 
of  approximately  200  pg/mL  in  cases  with  GFR  lower  than  60 
mL/min/1.73 m
2. Wang et al.
10) noted that a diagnosis of cardiac 
failure could be made with sensitivity and specificity of 66% and 
70%, respectively, using a BNP cut-off value of higher than 829 
pg/L  in  patients  with  CKD  in  whom  systolic  heart  failure  was 
absent. According to these authors, when the renal function was 
classified as moderate renal failure (60>Ccr≥30 mL/min), severe 
renal  failure  (30>Ccr≥15  mL/min)  and  end-stage  renal  failure 
(Ccr<15 mL/min), comparison of BNP level can be problematic. 
In cases with concurrent heart failure, however, the serum BNP 
concentration  was  significantly  elevated  in  patients  with  renal 
failure  of  corresponding  severity  (1,183±1,056,  2,205±1,470, 
3,209±1,900 pg/mL). In the present study, a diagnosis of heart 
failure could be made with sensitivity and specificity of 77% and 
72%, respectively, in the total CKD patient population when the 
concentration  of  serum  BNP  exceeded  858.5  pg/mL.  In 
comparison  with  other  studies,  our  figures  were  relatively  high. 
This  may  be  explained  by  the  fact  that  McCullough  et  al. 
excluded the dialysis group, unlike the present study, and Kim et 
al. used a BNP upper limit of 2,000 pg/mL (vs. 5,000 pg/mL in 
the  present  study).  In  our  series,  BNP  level  depending  on  the 
CKD stage was elevated with no relation to cardiac dysfunction 
in  CKD stage  5. This  may have been due  to the  effects of  left 
ventricular  hypertrophy,  impairment  of  relaxation  function, 
h e m o g l o b i n ,  a l b u mi n ,  a n d  d r u g s  u s e d  i n  t r e a t m e n t
4).
There  have  been  many  recent  studies  of  the  correlations 
between BNP level, cardiac function, and patient prognosis. Kim 
et al.
7) and Takayoshi et al.
14) reported that the concentration of 
serum  BNP  was  inversely  correlated  with  left  ventricle  ejection 
fraction.  Nitta  et  al.
15)  reported  that  the  mean  serum  BNP  con-
centration  was  higher  in  hemodialysis  patients  than  in  normal 
healthy  subjects,  and  there  was  an  inverse  correlation  between 
the  serum  BNP  concentration  and  the  left  ventricular  function. 
T h e  r e s u l t s  o f  t h e  p r e s e n t  s t u d y  a l s o  i n d i c a t e d  a n  i n v e r s e  
correlation  between  the  serum  BNP  concentration  and  left 
ventricle  ejection  fraction  on  echocardiography.  This  study  also 
indicated  that  serum  BNP  concentration  shows  an  inverse 
correlation with patient survival and a positive correlation with left 
ventricular  mass  index  (LVMI). 
I n  t h e  p r e s e n t  s t u d y ,  t h e  c u m u l a t i v e  s u r v i v a l  r a t e s  w e r e  
calculated  based  on  the  serum  BNP  concentration,  which  can 
be  used  for  diagnosis  of  heart  failure.  The  results  revealed  a 
significant  difference  in  patient  survival,  indicating  that  the 
concentration  of  serum  BNP  is  a  prognostic  indicator  for 
prediction of patient survival in patients with chronic renal failure 
as  well  as  those  with  normal  kidney  function.  In  another  study 
examining the correlation between serum BNP concentration and 
patient survival in patients with CKD, Yoichi et al.
5) analyzed the 
incidence of heart disease in patients with CKD who had normal 
heart  function.  These  authors  reported  significant  differences  in 
the incidence of cardiac disease and patient survival based on a 
BNP  cut-off  value  of  150  pg/mL.  Wendy  et  al.
12)  reported  that 
the incidence of heart disease increased and there are significant 
differences  in  patient  survival  based  on  a  cut-off  value  of  175 
pg/mL.  Moreover,  other  studies  have  also  indicated  that  the 
serum  BNP  concentration  is  a  useful  indicator  for  diagnosis  of 
left  ventricular  hypertrophy  or  left  ventricular  dysfunction  in 
hemodialysis  patients  with  CKD.  Furthermore,  it  has  also  been 
reported  that  the  serum  BNP  concentration  is  a  powerful 
i n d i c a t o r  f o r  p r e d i c t i o n  o f  p r o g n o s i s  i n  p a t i e n t s  i n  w h o m  
cardiovascular  diseases  are  accompanied  by  left  ventricular 
hypertrophy  or  left  ventricular  dysfunction
17, 18).
In the present study, the serum BNP concentration showed a 
positive correlation with that of serum creatinine in patients with 
CKD. Here, the cut-off value of BNP level was 858.5 pg/mL. In 
addition,  there  were  significant  differences  in  serum  BNP 
concentration  depending  on  the  presence  of  heart  failure  at 
identical  CKD  stages.  In  patients  with  CKD  stage  5,  however, 
the serum BNP concentration was relatively high with no relation 
t o  t h e  p r e s e n c e  o f  h e a r t  f a i l u r e ,  i n  c o m p a r i s o n  t o  t h o s e  w i t h  
CKD  stage  3  or  4.  These  results  indicate  that  assessment  of 
cardiac  function  based  on  the  concentration  of  serum  BNP 
depending  on  each  CKD  stage  will  be  useful  for  determining 
prognosis as well as for planning treatment in patients with CKD.
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